Opinion
Video
Author(s):
Paul E. Dato, MD, discusses how bone-targeted therapies play an important supportive role in advanced prostate cancer, with recommendations for calcium and vitamin D supplementation, vitamin K2 consideration, resistance exercises, and regular monitoring for all patients on ADT.
Clinical Brief: Bone-Targeted Therapies in Advanced Prostate Cancer
Main Discussion Topics
Key Points for Physicians
Notable Insights
While denosumab and zoledronic acid have established roles in castration-resistant disease, emerging evidence suggests potential benefits in hormone-sensitive settings that may influence future guideline recommendations.
Clinical Significance
Comprehensive bone health management is an essential component of prostate cancer care, requiring attention to both pharmacologic interventions and supportive measures to reduce fracture risk and maintain quality of life.